Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amgen (GB:0R0T)
LSE:0R0T
Amgen (0R0T) Share Price & Analysis
2 Followers
0R0T Stock Chart & Stats
Day’s Range$269.46 - $272.88
52-Week Range― - ―
Previous Close$265.5
Volume922.00
Average Volume (3M)N/A
Market Cap
$145.72B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 02, 2024EPS Estimate
$3.89Next Dividend Ex-Date
May 16, 2024Dividend Yield3.21%
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$310.41Price Target Upside14.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Amgen News
PremiumPress Releases
AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAMGN exhibits confidence in advancing Tezspire's development, with plans for Phase III trials targeting patients with high eosinophil counts, which could translate into a larger market reach and increased stock value.
Drug EfficacyTezspire demonstrates a significant reduction in COPD exacerbation rates, especially in patients with elevated eosinophil counts, suggesting a strong competitive edge in treatment effectiveness.
Market PotentialWith the potential to address a broader COPD patient population and a substantial market opportunity, Tezspire could become a leading treatment, offering improved convenience with less frequent dosing.
Bears Say
Competitive LandscapeCompetition in the obesity market is intensifying, with LLY and Novo leading and improving the standard of care.
Drug EfficacyThe overall phase 2 trial for Tezspire missed the primary endpoint, which might raise concerns about its efficacy.
Investor SentimentInvestor confidence in MariTide may be shaken due to the robustness of VK2735's trial results and its implications on market positioning.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.08% Insiders
21.25% Mutual Funds
28.00% Other Institutional Investors
49.67% Public Companies and
Individual Investors
0R0T FAQ
What was Amgen’s price range in the past 12 months?
Currently, no data Available
What is Amgen’s market cap?
Currently, no data Available
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is May 02, 2024 which is in 8 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Feb 06, 2024. The company reported $4.71 earnings per share for the quarter, beating the consensus estimate of $4.591 by $0.119.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.25 which represents an annual dividend yield of 3.21%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is $3.89.
How many shares outstanding does Amgen have?
Currently, no data Available
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $4.71 in its last earnings report, beating expectations of $4.591. Following the earnings report the stock price went down -5.329%.
Which hedge fund is a major shareholder of Amgen?
Among the largest hedge funds holding Amgen’s share is PRIMECAP Management Co. It holds Amgen’s shares valued at 4B.
---
Amgen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$310.41 (14.33% Upside)
$310.41 (14.33% Upside)
Blogger Sentiment
Bullish
GB:0R0T Sentiment 88%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.25%
12-Months-Change
Fundamentals
Return on Equity
135.79%
Trailing 12-Months
Asset Growth
49.19%
Trailing 12-Months
Company Description
Amgen
Founded in 1980, California-based Amgen, Inc. is one of the world's leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
---
0R0T Company Deck
---
0R0T Earnings Call
Q4 2024
0:00 / 0:00
---
0R0T Revenue Breakdown
14.36% Prolia
13.11% Enbrel
7.76% Otezla
7.49% XGEVA
57.27% Other
---
0R0T Stock 12 Months Forecast
Average Price Target
$310.41
▲(14.33% Upside)
Technical Analysis
Best Analysts Covering 0R0T
1 Year
1 Year Success Rate
21/27 ratings generated profit
1 Year Average Return
+15.02%
reiterated a buy rating 9 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +15.02% per trade.
---